Emergent BioSolutions Inc. — Director's Dealing 2020

Feb 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2020-02-25

Reporting Person: Strei Katherine (EVP, Chief HR Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-25	Common Stock	A	3662	—	Acquired	25850	Direct
2020-02-25	Common Stock	A	3662	—	Acquired	29512	Direct
2020-02-26	Common Stock	F	498	$59.91	Disposed	29014	Direct
2020-02-26	Common Stock	F	381	$59.91	Disposed	28633	Direct
2020-02-27	Common Stock	F	387	$58.42	Disposed	28246	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-25	Employee Stock Options (Right to Buy)	$61.44	A	14648	Acquired	2027-02-24	Common Stock (14648.0)	Direct

Footnotes

F1: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue for the three year period 2020 - 2022 fiscal years, as certified by the Compensation Committee following the performance period.

F3: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated.

F4: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company.